Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Neurontin
Active Ingredient(s): Gabapentin 100mg
Dosage Form: Capsule
New Zealand Sponsor: Parke Davis (Division Warner Lambert NZ Limited)
Manufacturer(s): Godecke AG, Freiburg, Germany
Product: Neurontin
Active Ingredient(s): Gabapentin 300mg
Dosage Form: Capsule
New Zealand Sponsor: Parke Davis (Division Warner Lambert NZ Limited)
Manufacturer(s): Godecke AG, Freiburg, Germany
Product: Neurontin
Active Ingredient(s): Gabapentin 400mg
Dosage Form: Capsule
New Zealand Sponsor: Parke Davis (Division Warner Lambert NZ Limited)
Manufacturer(s): Godecke AG, Freiburg, Germany
Product: Neurontin
Active Ingredient(s): Gabapentin 600mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Parke Davis (Division Warner Lambert NZ Limited)
Manufacturer(s): Parke Davis Pharmaceuticals Limited, Vega Baja, Puerto Rico
Product: Neurontin
Active Ingredient(s): Gabapentin 800mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Parke Davis (Division Warner Lambert NZ Limited)
Manufacturer(s): Warner-Lambert Inc, Vega Baja, Puerto Rico
Dated this 8th day of November 2000.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).